Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.

Burger D, Ewings F, Kabamba D, L'homme R, Mulenga V, Kankasa C, Thomason M, Gibb DM, Chintu C, Walker AS.

Ther Drug Monit. 2010 Jun;32(3):369-72. doi: 10.1097/FTD.0b013e3181d75e47.

PMID:
20386361
2.

A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.

Vanprapar N, Cressey TR, Chokephaibulkit K, Muresan P, Plipat N, Sirisanthana V, Prasitsuebsai W, Hongsiriwan S, Chotpitayasunondh T, Eksaengsri A, Toye M, Smith ME, McIntosh K, Capparelli E, Yogev R; IMPAACT P1056 Team.

Pediatr Infect Dis J. 2010 Oct;29(10):940-4. doi: 10.1097/INF.0b013e3181e2189d.

3.

Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets.

Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A, Ferrier A, Chintu C, Walker AS, Gibb DM, Burger DM.

AIDS. 2012 Sep 10;26(14):1795-800. doi: 10.1097/QAD.0b013e32835705fd.

PMID:
22739394
4.

Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.

Corbett AH, Hosseinipour MC, Nyirenda J, Kanyama C, Rezk NL, Mkupani P, Sichali D, Tien H, Kashuba AD, Mwansambo C, Weigel R, Kazembe P.

Antivir Ther. 2010;15(1):83-90. doi: 10.3851/IMP1488.

5.

A single-dose, randomized, open-label, two-period crossover bioequivalence study of a fixed-dose pediatric combination of lamivudine 40-mg, nevirapine 70-mg, and stavudine 10-mg tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.

Monif T, Rao Thudi N, Koundinya Tippabhotla S, Khuroo A, Marwah A, Kumar Shrivastav V, Tandon M, Raghuvanshi R, Biswal S.

Clin Ther. 2007 Dec;29(12):2677-84. doi: 10.1016/j.clinthera.2007.12.028.

PMID:
18201583
6.

Pharmacokinetics of nevirapine, stavudine and lamivudine in Indian HIV-infected children receiving generic fixed dose combinations.

Mukherjee A, Singla M, Velpandian T, Sirohiwal A, Vajpayee M, Singh R, Kabra SK, Lodha R.

Indian Pediatr. 2014 Mar;51(3):191-7.

7.

Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.

L'homme RF, Kabamba D, Ewings FM, Mulenga V, Kankasa C, Thomason MJ, Walker AS, Chintu C, Burger DM, Gibb DM.

AIDS. 2008 Mar 12;22(5):557-65. doi: 10.1097/QAD.0b013e3282f4a208.

PMID:
18316996
8.

Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.

Byakika-Tusiime J, Chinn LW, Oyugi JH, Obua C, Bangsberg DR, Kroetz DL.

PLoS One. 2008;3(12):e3981. doi: 10.1371/journal.pone.0003981. Epub 2008 Dec 19.

9.

Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.

Ellis JC, L'homme RF, Ewings FM, Mulenga V, Bell F, Chileshe R, Molyneux E, Abernethy J, van Oosterhout JJ, Chintu C, Walker AS, Gibb DM, Burger DM.

Antivir Ther. 2007;12(2):253-60.

PMID:
17503667
10.

Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.

Hosseinipour MC, Corbett AH, Kanyama C, Mshali I, Phakati S, Rezk NL, van der Horst C, Kashuba AD.

AIDS. 2007 Jan 2;21(1):59-64.

PMID:
17148968
11.

Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.

Chokephaibulkit K, Plipat N, Cressey TR, Frederix K, Phongsamart W, Capparelli E, Kolladarungkri T, Vanprapar N.

AIDS. 2005 Sep 23;19(14):1495-9.

PMID:
16135903
12.

Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.

Byakika-Kibwika P, Lamorde M, Kalemeera F, D'Avolio A, Mauro S, Di Perri G, Ryan M, Mayanja-Kizza H, Khoo S, Back D, Boffito M, Merry C.

J Antimicrob Chemother. 2008 Nov;62(5):1113-7. doi: 10.1093/jac/dkn290. Epub 2008 Jul 18.

13.

Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.

Chokephaibulkit K, Cressey TR, Capparelli E, Sirisanthana V, Muresan P, Hongsiriwon S, Ngampiyaskul C, Limwongse C, Wittawatmongkol O, Aurpibul L, Kabat B, Toye M, Smith ME, Eksaengsri A, McIntosh K, Yogev R; IMPAACT P1069 Team.

Antivir Ther. 2011;16(8):1287-95. doi: 10.3851/IMP1931.

14.

Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.

Pollock L, Else L, Poerksen G, Molyneux E, Moons P, Walker S, Fraser W, Back D, Khoo S.

J Antimicrob Chemother. 2009 Dec;64(6):1251-9. doi: 10.1093/jac/dkp358. Epub 2009 Oct 6.

15.
17.

Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults.

L'homme RF, Dijkema T, Warris A, van der Ven AJ, Gibb DM, Burger DM.

J Antimicrob Chemother. 2007 Jan;59(1):92-6. Epub 2006 Oct 28.

PMID:
17071953
18.

A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India.

Vezina HE, Henry K, Ravindran GD, Kurpad AV, Raj TD, Fox K, Weller D, Brundage RC, Cavert W, Balfour HH Jr.

J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):131-6.

PMID:
16394842
19.
20.

Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.

Poerksen G, Pollock L, Moons P, Chesshyre E, Burger D, Khoo S, Molyneux E.

Antivir Ther. 2010;15(3):343-50. doi: 10.3851/IMP1544.

Supplemental Content

Support Center